scholarly journals Current and Emerging Uses of Statins in Clinical Therapeutics: A Review

2016 ◽  
Vol 9 ◽  
pp. LPI.S37450 ◽  
Author(s):  
Jonathan T. Davies ◽  
Spencer F. Delfino ◽  
Chad E. Feinberg ◽  
Meghan F. Johnson ◽  
Veronica L. Nappi ◽  
...  
Keyword(s):  
Neurodegenerative Disorders ◽  
Bacterial Infections ◽  
Inflammatory Diseases ◽  
Conclusive Evidence ◽  
Atherosclerotic Cardiovascular Disease ◽  
Clinical Therapeutics ◽  
Therapeutic Uses ◽  
Immunodeficiency Virus ◽  
Autoimmune And Inflammatory Diseases ◽  
Statin Use

Statins, a class of cholesterol-lowering medications that inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, are commonly administered to treat atherosclerotic cardiovascular disease. Statin use may expand considerably given its potential for treating an array of cholesterol-independent diseases. However, the lack of conclusive evidence supporting these emerging therapeutic uses of statins brings to the fore a number of unanswered questions including uncertainties regarding patient-to-patient variability in response to statins, the most appropriate statin to be used for the desired effect, and the efficacy of statins in treating cholesterol-independent diseases. In this review, the adverse effects, costs, and drug–drug and drug–food interactions associated with statin use are presented. Furthermore, we discuss the pleiotropic effects associated with statins with regard to the onset and progression of autoimmune and inflammatory diseases, cancer, neurodegenerative disorders, strokes, bacterial infections, and human immunodeficiency virus. Understanding these issues will improve the prognosis of patients who are administered statins and potentially expand our ability to treat a wide variety of diseases.

scholarly journals Special issue—before translational medicine: laboratory clinic relations lost in translation? Cortisone and the treatment of rheumatoid arthritis in Britain, 1950–1960

2019 ◽  
Vol 41 (4) ◽  
Author(s):  
Michael Worboys ◽  
Elizabeth Toon
Keyword(s):  
Rheumatoid Arthritis ◽  
New York ◽  
Clinical Practice ◽  
Translational Medicine ◽  
Bacterial Infections ◽  
Skin Diseases ◽  
Inflammatory Diseases ◽  
New York Times ◽  
Childhood Leukaemia ◽  
Therapeutic Uses

Abstract Cortisone, initially known as ‘compound E’ was the medical sensation of the late 1940s and early 1950s. As early as April 1949, only a week after Philip Hench and colleagues first described the potential of ‘compound E’ at a Mayo Clinic seminar, the New York Times reported the drug’s promise as a ‘modern miracle’ in the treatment of rheumatoid arthritis (RA). Given its high profile, it is unsurprising that historians of medicine have been attracted to study the innovation of cortisone. It arrived at the end of a decade of ‘therapeutic revolutions’, kicked off by penicillin transforming the treatment of bacterial infections and ending with hopes of a revolution in the treatment of non-infectious, chronic inflammatory diseases. Despite these studies of cortisone’s introduction, few historians have taken the story forward and considered how cortisone was adopted and adapted into clinical practice. This article tells the longer of how the drug and its derivatives were taken from research laboratories and integrated into clinical practice; what has in recent decades become known as translational medicine (TM). In exploring cortisone’s first decade in Britain, we focus specifically on its role in the treatment of RA. Our approach is always to consider cortisone’s use in the context of other treatments available to clinicians, and at local and national institutional settings. We do not discuss the many other therapeutic uses of cortisone, which ranged for topical applications for skin diseases to the management of cancers, especially childhood leukaemia, nor do we discuss its close analogue ACTH—AdenoCorticoTropic Hormone. We think there are lessons in our study for TM policies today.

scholarly journals Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives

2021 ◽  
Vol 11 (5) ◽  
pp. 336
Author(s):  
Mohammed Ghiboub ◽  
Ahmed M. I. Elfiky ◽  
Menno P. J. de Winther ◽  
Nicola R. Harker ◽  
David F. Tough ◽  
...  
Keyword(s):  
Histone Deacetylases ◽  
Inflammatory Diseases ◽  
Selective Inhibition ◽  
In Vivo Studies ◽  
Beneficial Effects ◽  
Domain Specific ◽  
Recent Advances ◽  
Autoimmune And Inflammatory Diseases

Histone deacetylases (HDACs) and bromodomain-containing proteins (BCPs) play a key role in chromatin remodeling. Based on their ability to regulate inducible gene expression in the context of inflammation and cancer, HDACs and BCPs have been the focus of drug discovery efforts, and numerous small-molecule inhibitors have been developed. However, dose-limiting toxicities of the first generation of inhibitors, which typically target multiple HDACs or BCPs, have limited translation to the clinic. Over the last decade, an increasing effort has been dedicated to designing class-, isoform-, or domain-specific HDAC or BCP inhibitors, as well as developing strategies for cell-specific targeted drug delivery. Selective inhibition of the epigenetic modulators is helping to elucidate the functions of individual epigenetic proteins and has the potential to yield better and safer therapeutic strategies. In accordance with this idea, several in vitro and in vivo studies have reported the ability of more selective HDAC/BCP inhibitors to recapitulate the beneficial effects of pan-inhibitors with less unwanted adverse events. In this review, we summarize the most recent advances with these strategies, discussing advantages and limitations of these approaches as well as some therapeutic perspectives, focusing on autoimmune and inflammatory diseases.

scholarly journals The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections

Biology ◽  
2020 ◽  
Vol 9 (8) ◽  
pp. 192 ◽  
Author(s):  
Paulina Glowacka ◽  
Lidia Rudnicka ◽  
Olga Warszawik-Hendzel ◽  
Mariusz Sikora ◽  
Mohamad Goldust ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Influenza Virus ◽  
Hepatitis C ◽  
Beneficial Effect ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Skin Diseases ◽  
Current Knowledge ◽  
Immunosuppressive Treatment ◽  
Immunodeficiency Virus

This review updates current knowledge regarding the risk of viral infections, including COVID-19, in patients treated with cyclosporine. We also shortly refer to bacterial infections and parasitic infestations in patients treated with cyclosporin. Cyclosporine is an immunosuppressive drug, which is widely used in medicine, including in the treatment of autoimmune skin diseases in dermatology, rheumatology, ophthalmology and nephrology, and in organ transplantation. A usual concern associated with immunosuppressive treatment is the potential risk of infections. Interestingly, several data indicate a relatively low risk of infections, especially viral infections, in patients receiving cyclosporine. It was shown that cyclosporine exerts an inhibitory effect on the replication of some viruses, or may have a potentially beneficial effect on the disease course in infections. These include hepatitis C, influenza virus, rotavirus, human immunodeficiency virus and coronavirus infections. Available data indicate that cyclosporine may have a beneficial effect on COVID-19, which is caused by the coronavirus SARS-COV2.

scholarly journals Roles of XBP1s in Transcriptional Regulation of Target Genes

Biomedicines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 791
Author(s):  
Sung-Min Park ◽  
Tae-Il Kang ◽  
Jae-Seon So
Keyword(s):  
Transcriptional Regulation ◽  
Er Stress ◽  
Target Genes ◽  
Inflammatory Diseases ◽  
Vital Role ◽  
Genes Encoding ◽  
Autoimmune And Inflammatory Diseases ◽  
Active Transcription ◽  
Transcriptional Regulatory Mechanisms ◽  
The Unfolded Protein Response

The spliced form of X-box binding protein 1 (XBP1s) is an active transcription factor that plays a vital role in the unfolded protein response (UPR). Under endoplasmic reticulum (ER) stress, unspliced Xbp1 mRNA is cleaved by the activated stress sensor IRE1α and converted to the mature form encoding spliced XBP1 (XBP1s). Translated XBP1s migrates to the nucleus and regulates the transcriptional programs of UPR target genes encoding ER molecular chaperones, folding enzymes, and ER-associated protein degradation (ERAD) components to decrease ER stress. Moreover, studies have shown that XBP1s regulates the transcription of diverse genes that are involved in lipid and glucose metabolism and immune responses. Therefore, XBP1s has been considered an important therapeutic target in studying various diseases, including cancer, diabetes, and autoimmune and inflammatory diseases. XBP1s is involved in several unique mechanisms to regulate the transcription of different target genes by interacting with other proteins to modulate their activity. Although recent studies discovered numerous target genes of XBP1s via genome-wide analyses, how XBP1s regulates their transcription remains unclear. This review discusses the roles of XBP1s in target genes transcriptional regulation. More in-depth knowledge of XBP1s target genes and transcriptional regulatory mechanisms in the future will help develop new therapeutic targets for each disease.

Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease

2021 ◽  
Author(s):  
Gabriela Spencer‐Bonilla ◽  
Sukyung Chung ◽  
Ashish Sarraju ◽  
Paul Heidenreich ◽  
Latha Palaniappan ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Older Adults ◽  
Atherosclerotic Cardiovascular Disease ◽  
Statin Use

Baseline Lipid Profiles and Statin Use among Patients with Atherosclerotic Cardiovascular Disease

2015 ◽  
Vol 9 (3) ◽  
pp. 441
Author(s):  
Peter P. Toth ◽  
Xuehua Ke ◽  
Zhenxiang Zhao ◽  
Nicole Bonine ◽  
Mark Cziraky ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Lipid Profiles ◽  
Atherosclerotic Cardiovascular Disease ◽  
Statin Use

Statin Use With the ATP III Guidelines Compared to the 2013 ACC/AHA Guidelines in HIV Primary Care Patients

2016 ◽  
Vol 30 (1) ◽  
pp. 64-69 ◽  
Author(s):  
Pansy Elsamadisi ◽  
Agnes Cha ◽  
Elise Kim ◽  
Safia Latif
Keyword(s):  
Statin Therapy ◽  
Retrospective Chart Review ◽  
Population Based ◽  
Risk Scores ◽  
Atherosclerotic Cardiovascular Disease ◽  
Laboratory Test Results ◽  
Hiv Primary Care ◽  
Cholesterol Guidelines ◽  
Level Of Agreement ◽  
Statin Use

Background: The 2013 Cholesterol Guidelines include a new atherosclerotic cardiovascular disease (ASCVD) risk calculator that determines the 10-year risk of coronary heart disease and/or stroke. The applicability of this calculator and its predecessor, the Framingham risk score (FRS) in Adult Treatment Panel (ATP) III, has been limited in patients with HIV. The objective of this study was to compare the risk scores of ASCVD and FRS in the initiation of statin therapy in patients with HIV. Methods: We conducted a retrospective chart review of patients with HIV on statin therapy from October 1, 2013, to April 1, 2014. Data collection included patient demographics, pertinent laboratory test results, and medication list. The primary end point evaluated the level of agreement between the guidelines. Results: Of 155 patients who met the inclusion criteria, 116 were treated similarly with both guidelines. This showed a moderate level of agreement ( P < .001). Forty-eight of 86 patients requiring statins were placed on the correct intensity statin using the 2013 guidelines. Regardless of which guideline, a majority of patients required statin therapy. Conclusion: A moderate agreement was found between both guidelines in terms of statin use when applied to an HIV patient population. Based on the 2013 guidelines and taking into account drug interactions with antiretrovirals, 44.2% of the patients were treated with an incorrect statin intensity.

Sign in / Sign up

Export Citation Format

Share Document